Last updated on April 2019

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Brief description of study

The primary purpose of this study is to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

Clinical Study Identifier: NCT03093480

Contact Investigators or Research Sites near you

Start Over

University of Michigan

Ann Arbor, MI United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Children's Hospital Los Angeles

Los Angeles, CA United States
  Connect »

Michigan State University

East Lansing, MI United States
  Connect »

El Paso Children's Hospital

El Paso, TX United States
  Connect »

Cook Children's Medical Center

Fort Worth, TX United States
  Connect »

St Thomas' Hospital

London, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.